ConcertAI and NeoGenomics have unveiled an innovative software-as-a-service (SaaS) solution aimed at revolutionizing hematology clinical research. This groundbreaking platform, known as CTO-H, offers unparalleled research data capabilities to enhance analytics, trial design, and operational efficiency in clinical trials.
Setting a New Benchmark in Hematology Research
CTO-H stands out by providing a comprehensive dataset that includes longitudinal data spanning 7 to 11 years for over 370,000 patients. It combines clinical attributes with in-depth biomarker insights, ranging from routine tests to specialized genetic variants. This makes it the most extensive reference database for hematological malignancies ever created, redefining what’s possible in clinical research.
Addressing Challenges in Hematological Clinical Trials
The complexity of hematological research lies in its diverse treatment standards, longer treatment durations, and intricate measures of disease response. CTO-H addresses these challenges by enabling precise study designs and optimizing trial execution. It helps researchers overcome hurdles like identifying representative control groups for early-phase trials and managing competition for participants in late-phase studies.
Dr. Jeff Elton, the founding CEO of ConcertAI, emphasized the platform’s significance by stating, “Hematological research is inherently complex. CTO-H represents a major leap forward in advanced clinical analysis, study planning, and execution.”
NeoGenomics’ Expertise Strengthens the Collaboration
NeoGenomics, a leader in clinical diagnostics with over 500 tests, brings its expertise to the partnership by contributing advanced biomarker interpretation and specialized clinical insights. Lindsey Gasparini, Vice President of Informatics at NeoGenomics, remarked, “This solution enables biopharma to rethink how they design clinical trials, boosting precision and cutting down timelines, ultimately accelerating biomedical innovation for patients.”
SaaS Deployment and Future Availability
ConcertAI plans to deploy CTO-H via its CARAai™ cloud platform, while NeoGenomics will support biomarker analysis and provide clinical expertise. CTO-H is currently available as a pre-release for evaluation, with general availability slated for January 17, 2025.
Looking Ahead
With its ability to streamline clinical trial design and execution, CTO-H represents a significant milestone in hematology research. This collaboration between ConcertAI and NeoGenomics is expected to accelerate the development of groundbreaking therapies, ultimately benefiting patients and healthcare providers worldwide.
For more insights on how AI is transforming industries, check out How AI Shapes 61% of Brand Content and Enhances Corporate Trust.